Stem Cell Type Slow to Multiply
Posted on: Monday, 5 January 2009, 08:22 CST
A type of stem cell responsible for all blood and immune system cells reproduces much more slowly than expected.
Using this subpopulation of hematopoietic stem cells may help treatment of leukemia and other marrow-based diseases by improving the outcome of stem cell transplants, also referred to as bone marrow transplants.
The entire population of hematopoietic stem cells (HSCs) in bone marrow are believed to reproduce at a rate of about 7 percent per day, with each cell dividing every two weeks; however, previous studies appear to have missed that some cells divide much less frequently. Massachusetts General Hospital (MGH) researchers found while 80 percent of HSCs reproduce at the expected rate, the rest do so much more slowly, only dividing every 100 days or even longer.
"Hematopoietic stem cell transplantation saves many lives every day and is the most established therapeutic application of stem cells, but ironically we know very little about the cells that have made this clinical success possible," Hanno Hock, M.D., Ph.D., lead researcher and an assistant professor at MGH's Center for Regenerative Medicine in Boston, was quoted as saying. "If we can improve our understanding of the biology of these cells, we should be able to offer our patients more therapeutic options."
SOURCE: Nature Biotechnology, published online December 5, 2008
---
On the Net:
Source: Ivanhoe
Related Articles
- Neural Stem Cell Differentiation Factor Found
- Proteonomix, Inc. (PROT) Announces the Launch of Its Line of Anti-Aging Stem Cell Derived Cosmetics
- AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury
- Stem Cells Make Bone Marrow Cancer Resistant To Treatment
- CellTraffix Technology Separates Adult Stem Cells From Bone Marrow
- French and U.S. Physicians Say a Simple, Point-of-Care System for Concentrating Autologous Adult Stem Cells From Bone Marrow Is Enabling European Clinicians to Offer New Therapies for a Variety of Serious Diseases, With No Reported Side Effects
- Pluristem Announces Advanced Engineered Cell Graft to Improve Resurgence of the Hematopoietic Stem Cells in Bone Marrow for Cancer Patients; Pre-Clinical Animal Model Testing Underway
- Quest Diagnostics Unveils New Data Confirming Benefits Of Leukemia Tests Using Blood Plasma, Compared With Conventional Tests Using Cells In Bone Marrow Or Blood, At American Society Of Hematology Meeting
- CNS Foundation Joins A-TCP in Funding Stem-Cell Based Therapies
- Correlation Between Serum Levels of Free Light Chain and Phenotype of Plasma Cells in Bone Marrow in Primary AL Amyloidosis
 |
 |
User Comments (0)
RSS Feeds